Clinical Trials Logo

Clinical Trial Summary

Acquired drug-resistance is a major challenge for tuberculosis (TB) care programs. The 2020 WHO guidelines recommends replacing second-line injectables by bedaquiline in rifampicin-resistant TB (RR-TB) treatment regimens. However, recent reports show too high rates of acquired bedaquiline resistance. This may be explained by the delayed onset of action of bedaquiline. The investigators will study whether high-dose amikacin (a second-line injectable), administered during the first week of RR-TB treatment, is safe in 20 patients treated for RR-TB in Rwanda. If safe, further studies will assess whether adding amikacin in the first treatment week protect against acquired bedaquiline resistance. This study is embedded in an ongoing "Master study" of the ShORRT (short oral RR-TB) treatment regimen in Rwanda, a before/after study, with a retrospective cohort (before; the previously recommended second-line injectable-containing RR-TB regimen) and a prospective cohort (after: the newly recommended ShORRT regimen).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05555303
Study type Interventional
Source Rwanda Biomedical Centre
Contact Yves Habimana-Mucyo, MSc
Phone +250733436765
Email yves.mucyo@rbc.gov.rw
Status Recruiting
Phase Phase 2
Start date March 1, 2023
Completion date February 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05871489 - Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Active, not recruiting NCT04179500 - A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers Phase 2
Completed NCT03086486 - Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis Phase 3
Completed NCT01201941 - Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru N/A
Not yet recruiting NCT06441006 - Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis Phase 3
Completed NCT03303963 - DIAgnostics for Multidrug Resistant Tuberculosis in Africa
Completed NCT02413931 - Nosocomial Transmission of MDR-TB in Bucharest, Romania
Recruiting NCT05306223 - A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China Phase 4
Completed NCT02573350 - A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 Phase 2
Completed NCT02597621 - Biomarkers for Therapy Response in Drug-resistant Tuberculosis
Recruiting NCT03828201 - Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB Phase 2
Recruiting NCT01212003 - Training Protocol on the Natural History of Tuberculosis
Terminated NCT03237182 - The Individualized M(X) Drug-resistant TB Treatment Strategy Study Phase 4
Completed NCT03338621 - Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Phase 2/Phase 3
Not yet recruiting NCT05007795 - Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis N/A
Completed NCT03728725 - Xpert MTB/XDR Clinical Evaluation Trial
Completed NCT02589782 - Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) Phase 2/Phase 3
Recruiting NCT02619994 - Treatment Shortening of MDR-TB Using Existing and New Drugs Phase 2
Completed NCT01918397 - Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB Phase 2